VET-STEM INC.

What VET-STEM INC. does

VET-STEM INC. (VetStem) is a Poway, California-based veterinary biotechnology company founded in 2002 that develops and commercializes stem cell-based regenerative therapies for companion animals. Its core technology centers on autologous and allogeneic stem cell processing for the treatment of degenerative conditions in dogs, with canine osteoarthritis as the lead indication. The company's primary product, StemStat™, is a stem cell therapy specifically developed for canine osteoarthritis and is currently advancing through the FDA conditional approval process, supported by a strategic funding round secured in March 2025. VetStem positions itself as a niche innovator in animal regenerative medicine alongside major animal health companies such as Zoetis, targeting a global animal regenerative therapies market projected to expand from USD 370 million in 2025 to USD 870 million by 2032.

VetStem's business model is built on developing and selling stem cell therapy products to veterinary healthcare providers, principally companion animal clinics and hospitals treating dogs with chronic joint disease. The company operates with a sales-led go-to-market motion focused on veterinary clinic partnerships and professional distribution channels, with revenue derived from product sales described as one-time license transactions. Customer segmentation is vertical, concentrating on the companion animal healthcare segment for canine osteoarthritis treatment, addressing the unmet need for disease-modifying options beyond conventional pain management.

The company is privately held, employs 11-50 people, and remains a single-product-focused firm with StemStat™ as its commercial flagship. Its competitive posture relies on regulatory credibility (FDA conditional approval pursuit), proprietary stem cell technology, and two decades of operating experience in veterinary regenerative medicine. Distribution and marketing channel details, pricing structure, named customers, and ownership composition are not disclosed in the available source material.

Name

VET-STEM INC.

Website

https://vetstem.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

VetStem is a Poway, California-based veterinary biotechnology company founded in 2002 that develops stem cell-based regenerative therapies for companion animals, with its lead product StemStat™ advancing through FDA conditional approval for canine osteoarthritis treatment.

Ownership category

akta.pro rank

Product category

Veterinary Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA)

akta.pro secondary industries

Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI), Veterinary Vaccines (Biologics) (HLAMAEAL)

Keywords

• Veterinary stem cell therapy
• Animal regenerative medicine
• Canine osteoarthritis treatment
• Veterinary biopharmaceuticals
• Companion animal biotechnology

Headquarters

HQ city

Poway

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Stem Cell Therapy Products: VetStem generates revenue through the development and commercialization of veterinary stem cell therapies. As a biotechnology company advancing stem cell products through regulatory approval, revenue is derived from product sales to veterinary clinics and animal healthcare providers treating companion animals.

Go-to-market motion1 record

Core offering

VET-STEM INC. develops and commercializes proprietary stem cell-based regenerative therapies for veterinary use. The company's flagship product, StemStat™, is a stem cell therapy designed for the treatment of canine osteoarthritis and is currently undergoing the FDA conditional approval process. VetStem operates as a single-product-focused veterinary biotechnology firm targeting veterinary clinics and animal healthcare providers treating companion animals with degenerative conditions.

Product overview

VET-STEM INC. (VetStem) is a veterinary biotechnology company specializing in animal regenerative therapies. The company operates as a single-product-focused firm with its primary offering being StemStat™, a stem cell therapy product specifically developed for treating canine osteoarthritis. VetStem is actively pursuing FDA conditional approval for StemStat™ and is working to expand treatment options and market accessibility in the veterinary regenerative medicine space.

Differentiator

Problem solved

Functional benefit

Brands

• StemStat™: Veterinary stem cell product for treatment of canine osteoarthritis, currently seeking FDA conditional approval.

Products and services

• StemStat™ A proprietary stem cell therapy product designed for the treatment of canine osteoarthritis. Currently undergoing the FDA conditional approval process. Targeted at veterinary clinics and animal healthcare providers treating companion animals, primarily dogs, with degenerative joint conditions.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• ZoetiscoreStrategic or Co-development PartnerVetStem is identified alongside Zoetis as key companies advancing innovations in the animal regenerative therapies market. Both companies are contributing to market growth through stem cell therapies and digital integration to expand treatment options and market accessibility for veterinary applications.

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Zoetis: The world's largest animal health company, identified alongside VetStem as a key driver of the animal regenerative therapies market. Zoetis has substantially greater commercial, R&D, and distribution resources and competes in veterinary stem cell and biologic therapeutics.

Direct peers

• Regeneus: Australian clinical-stage regenerative medicine company developing cell-based therapies for both human and veterinary applications, including osteoarthritis. Operates in the same stem cell therapy category as VetStem but with broader species and indication reach.
• Ardent Animal Health: Veterinary regenerative medicine company offering autologous stem cell therapy for dogs with osteoarthritis and other orthopedic conditions. Direct head-to-head competitor in the canine stem cell therapy space that VetStem addresses with StemStat™.
• MediVet (Animal Health Partners): Veterinary regenerative medicine company providing stem cell and platelet-rich plasma therapies to companion animal practices. Overlaps directly with VetStem's product offering and veterinary clinic channel.

Emerging players

• Companion Animal Health (LiteCure): Provides regenerative therapy equipment and protocols (laser, PEMF) to veterinary clinics, with overlapping value proposition of disease-modifying treatment for canine osteoarthritis. Competes for the same veterinary practice channel and therapeutic use case.
• AniCell Biotech: Regenerative veterinary medicine company using amnion-derived stem cell and growth factor products for equine and companion animal injuries. Adjacent competitor in animal regenerative therapies with overlapping customer base of veterinary clinics.
• Vetbiologics: Veterinary biologics company focused on regenerative therapies and biologic products for animal health, including stem cell services. Closely comparable business model and target customer base to VetStem.
• SentrX Animal Care: Animal health company developing bioengineered regenerative and wound-healing products including stem cell-derived therapies. Comparable technology platform focused on animal healing and regeneration.
• Polygem (EquiStem): Provides stem cell therapies targeted primarily at equine musculoskeletal conditions, with applicability to companion animals. Adjacent competitor in veterinary regenerative medicine using similar autologous stem cell approaches.

Regional players

• VetStem (Australia): Australian affiliate/distributor of VetStem's stem cell technology, providing the same stem cell therapy services to companion animal veterinarians in Australia. Same technology platform but operates in a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vetstem
• LinkedInlinkedin.com/company/vet-stem-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VET-STEM INC.